Immunovia AB (publ) (STO:IMMNOV)
0.1296
-0.0022 (-1.67%)
Sep 4, 2026, 5:29 PM CET
Immunovia AB Revenue
Immunovia AB had revenue of 424.00K SEK in the quarter ending March 31, 2026, with 110.95% growth. This brings the company's revenue in the last twelve months to 975.00K, down -24.48% year-over-year. In the year 2025, Immunovia AB had annual revenue of 752.00K, down -55.61%.
Revenue (ttm)
975.00K
Revenue Growth
-24.48%
P/S Ratio
71.99
Revenue / Employee
67.28K
Employees
18
Market Cap
87.18M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 752.00K | -942.00K | -55.61% |
| Dec 31, 2024 | 1.69M | -108.00K | -5.99% |
| Dec 31, 2023 | 1.80M | 598.00K | 49.67% |
| Dec 31, 2022 | 1.20M | 248.00K | 25.94% |
| Dec 31, 2021 | 956.00K | -30.00K | -3.04% |
| Dec 31, 2020 | 986.00K | 172.00K | 21.13% |
| Dec 31, 2019 | 814.00K | -263.00K | -24.42% |
| Dec 31, 2018 | 1.08M | -23.17M | -95.56% |
| Dec 31, 2017 | 24.25M | -254.10K | -1.04% |
| Dec 31, 2016 | 24.50M | 7.50M | 44.07% |
| Dec 31, 2015 | 17.01M | 16.47M | 3,084.89% |
| Dec 31, 2014 | 534.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.24B |
| Swedish Orphan Biovitrum AB | 30.62B |
| Medicover AB | 27.33B |
| Sectra AB | 3.65B |
| IDL Diagnostics AB | 58.95M |
| Newbury Pharmaceuticals AB | 35.02M |
| Spago Nanomedical AB | 3.81M |
| Prostatype Genomics AB | 1.01M |
Immunovia AB News
- 4 weeks ago - Immunovia AB Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Immunovia AB Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Immunovia AB Slides: Q2 2026 - Filings
- 4 months ago - Immunovia AB Earnings Call Transcript: Q1 2026 - Transcripts
- 4 months ago - Immunovia AB Quarterly report: Q1 2026 - Filings
- 4 months ago - Immunovia AB Slides: Q1 2026 - Filings
- 6 months ago - Immunovia AB Earnings Call Transcript: Q4 2025 - Transcripts
- 6 months ago - Immunovia AB Annual report: Q4 2025 - Filings